{
  "docId": "019de071-1bdd-70bb-9c61-980d0c38b663",
  "docSlug": "a4792f18c57ea3f4ba27e696a63520de",
  "documentTitle": "AstraZeneca | Investor Day Presentation Deck | 40 slides",
  "authorId": "astrazeneca",
  "authorName": "AstraZeneca",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2021-06-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.4148858,
  "pageNumber": 27,
  "pageCount": 40,
  "prevPage": 26,
  "nextPage": 28,
  "slideType": "key_takeaways",
  "function": "analyze_data",
  "density": "dense",
  "nDataPoints": 12,
  "notes": "Data from ELEVATE-TN Phase III trial presented at ASCO 2021.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de071-1bdd-70bb-9c61-980d0c38b663/27",
  "deckHref": "/decks/019de071-1bdd-70bb-9c61-980d0c38b663",
  "deckJsonHref": "/decks/019de071-1bdd-70bb-9c61-980d0c38b663.json",
  "deckAnchorHref": "/decks/019de071-1bdd-70bb-9c61-980d0c38b663#slide-27",
  "components": [
    {
      "bbox": {
        "h": 0.22,
        "w": 0.42,
        "x": 0.28,
        "y": 0.53
      },
      "kind": "chart",
      "text": "Kaplan-Meier plot for patients with del(17p) and/or mutated TP53",
      "attrs": null,
      "subkind": "line",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9d207c91-1b81-4c0f-9665-41bc1e5e03f9",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.22,
        "w": 0.42,
        "x": 0.28,
        "y": 0.28
      },
      "kind": "chart",
      "text": "Kaplan-Meier plot for overall population",
      "attrs": null,
      "subkind": "line",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d9d2c87f-82b5-49d9-b685-32ad7c2a41d9",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.6,
        "x": 0.04,
        "y": 0.79
      },
      "kind": "paragraph",
      "text": "Hazard ratio was based on unstratified Cox-Proportional-Hazards model; P-value was based on unstratified log-rank test. Notes: A = Calquence (acalabrutinib) O = obinutuzumab, a 2nd-generation CD20 monoclonal antibody Cb = chlorambucil, a standard-of-care chemotherapy. Source: abstract 7509, ASCO 2021.",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "3975d875-b14d-4d29-89b6-66cc4e4bd55c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.75,
        "x": 0.04,
        "y": 0.19
      },
      "kind": "title",
      "text": "Sustained patient benefit at four years in a front-line setting",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6c683322-5a8f-43fd-9158-129a120d3401",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.75,
        "x": 0.04,
        "y": 0.14
      },
      "kind": "title",
      "text": "Calquence at ASCO: ELEVATE-TN Phase III trial",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b631fdaf-eeb5-4a49-9d40-ba35b46c717d",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 40,
      "from": 21,
      "beatId": "9bb24be0-c8c7-49aa-a526-e9fcc4794b51",
      "arcName": "Monroe's Motivated Sequence",
      "arcSlug": "monroes-sequence",
      "beatName": "Action",
      "beatSlug": "monroes-sequence-action",
      "evidence": "The document concludes with a call to action and next steps for investors.",
      "position": 3,
      "confidence": 0.8,
      "parentBeatName": "Resolution",
      "parentBeatSlug": "resolution"
    }
  ],
  "loops": [
    {
      "to": 28,
      "from": 21,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "cde01b8e-53ce-45e4-b3c4-d519c08ca374",
      "evidence": "The document implies that not investing in oncology would result in missed opportunities for growth and patient benefit.",
      "position": 1,
      "objective": "What are the consequences of not investing in oncology?",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.6,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}